Results 81 to 90 of about 790,254 (306)

Primary and Secondary Prevention of Obesity

Journal of Education, Health and Sport
Introduction and purpose: Obesity is a persistent and recurring chronic condition marked by an excessive accumulation of body fat, which can deteriorate health, heighten the risk of complications, and shorten life expectancy.This review provides a ...
Aleksandra Kiełczewska, Grzegorz Szcześniak, Anna Kiełczewska   +2 more
doaj   +1 more source

Survivin and Aurora Kinase A control cell fate decisions during mitosis

Molecular Oncology, EarlyView.
Aurora A interacts with survivin during mitosis and regulates its centromeric role. Loss of Aurora A activity mislocalises survivin, the CPC and BubR1, leading to disruption of the spindle checkpoint and triggering premature mitotic exit, which we refer to as ‘mitotic slippage’.
Hana Abdelkabir, Shalitha Wickrama Arachchige, Sally P. Wheatley   +2 more
wiley   +1 more source

CDK11 inhibition induces cytoplasmic p21WAF1 splice variant by p53 stabilisation and SF3B1 inactivation

Molecular Oncology, EarlyView.
CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.
Radovan Krejcir, Lukasz Arcimowicz, Lucia Martinkova, Vaclav Hrabal, Filip Zavadil Kokas, Tomas Henek, Martina Kucerikova, Ondrej Bonczek, Pavlina Zatloukalova, Lenka Hernychova, Philip J. Coates, Borivoj Vojtesek, David P. Lane   +12 more
wiley   +1 more source

Use of Antiplatelets for Primary and Secondary Prevention of Cardiovascular Events in the Medical Outpatient Setting of a Tertiary Centre in Nigeria: A Six-Month Review

Nigerian Journal of Medicine
Background: Cardiovascular disease (CVD) is the leading cause of death globally. The use of antiplatelets in the secondary prevention of CVD is well established. Their role in primary prevention of CVD is uncertain.
Uzoma Chukwunonso Okechukwu, Chinweuba Michael Abonyi, Christian Chukwuemeka Eze   +2 more
doaj   +1 more source

Primary and Secondary Prevention of Cardiovascular Disease in the Era of the Coronavirus Pandemic

, 2020
Eamon Duffy, Miguel Cainzos‐Achirica, Erin D. Michos   +2 more
openalex   +2 more sources

The Effects of Different Aspirin Dosing Frequencies and the Timing of Aspirin Intake in Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review [PDF]

, 2016
Danai Bem, Marie Lordkipanidzé, James Hodgkinson, Simon Stevens, Susan Bayliss, David Moore, David Fitzmaurice, Janine Dretzke   +7 more
openalex   +1 more source

Reduced vascular leakage correlates with breast carcinoma T regulatory cell infiltration but not with metastatic propensity

Molecular Oncology, EarlyView.
A mouse model for vascular normalization and a human breast cancer cohort were studied to understand the relationship between vascular leakage and tumor immune suppression. For this, endothelial and immune cell RNAseq, staining for vascular function, and immune cell profiling were employed.
Liqun He, Chiara Testini, Neda Hekmati, Altea Bonello, Aglaia Schiza, Emmanuel Nwadozi, Mia Phillipson, Carina Strell, Michael Welsh   +8 more
wiley   +1 more source

Combination niacin and statin therapy in primary and secondary prevention of cardiovascular disease [PDF]

, 2005
Deborah R Levy, Thomas A. Pearson
openalex   +1 more source

Models of Follow-Up Care and Secondary Prevention Measures for Survivors of Colorectal Cancer: Evidence-Based Guidelines and Systematic Review [PDF]

, 2022
Jacqueline Galica, Caroline Zwaal, Erin Kennedy, Tim Asmis, Charles Cho, Alexandra Ginty, Anand Govindarajan   +6 more
openalex   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source